Esthesioneuroblastoma, Olfactory
Nasal Cavity
Neuroectodermal Tumors, Primitive, Peripheral
Olfactory Bulb
Olfactory Receptor Neurons
Esthesioneuroblastoma is not a member of the primitive peripheral neuroectodermal tumour-Ewing's group. (1/49)
Esthesioneuroblastoma (ENB) is a rare, site-specific, locally aggressive neuronal malignancy so far thought to belong to primitive peripheral neuroectodermal tumour-Ewing's tumour (pPNETs-ETs). Its anatomical location, in addition to morphologic, immunophenotypic and ultrastructural features, suggests its origin in the neuronal or neuroendocrine cells of the olfactory epithelium. However, the cytogenetic and molecular data currently available appear controversial on the presence of the typical translocation t(11;22)(q24;q12) and of trisomy 8, chromosomal changes that characterize the tumours belonging to the pPNETs-ETs. Herein we have analysed five ENB tumour specimens for trisomy 8 by fluorescence in situ hybridization (FISH), for the presence of EWS gene rearrangements by FISH, reverse transcription polymerase chain reaction and Southern blot analyses, as well as for the expression of the Ewing sarcoma-associated MIC2 antigen by immunohistochemistry. Neither EWS/FLI-I, EWS/ERG and EWS/FEV fusion genes nor MIC2 expression were found in any tumour, whereas trisomy 8 was found in one case only. Moreover, DNA from three cases analysed by Southern blot did not show EWS gene rearrangements. Our results support the evidence that ENB is not a member of the pPNETs-ETs. (+info)Esthesioneuroblastoma: case report. (2/49)
Esthesioneuroblatoma (ENB) is a rare tumor arising from the olfactory epithelium of the nasal vault which frequently invades the cranial base, cranial vault and orbit. ENB has a bimodal age distribution between 11 and 20 years and between 51 and 60 years. ENB accounts for approximately 1 to 5% of intranasal cancers and no consensus has been reached regarding treatment of this tumor. We report on a 66 year old female patient with a Kadish stage C tumor with frontal lobe invasion submitted a total craniofacial resection with a combined head neck and neurosurgeon team. The purpose of this study is to analyze the natural history, treatment and prognosis of this tumor, based on the literature review. (+info)Treatment of intracranial metastatic esthesioneuroblastoma. (3/49)
BACKGROUND: Esthesioneuroblastoma (ENB) is an uncommon tumor that may metastasize to the central nervous system (CNS). To the authors' knowledge there is no current consensus regarding treatment. The current study was conducted to determine the toxicity and response rate of combined modality therapy in the treatment of patients with ENB metastatic to the brain. METHODS: Six patients (2 men and 4 women) ranging in age from 47-61 years (median age, 53.5 years) with ENB had clinical and neuroradiographic evidence of CNS metastases (brain parenchyma in 6 patients and leptomeningeal metastases in 3 patients). CNS-directed therapy included radiotherapy (to the brain in three patients and to the spine in two patients) and chemotherapy (systemic in six patients and regional in three patients). Systemic chemotherapy was comprised of carboplatin, lomustine, and vincristine administered every 2 months. Patients were evaluated by neuroradiographic and neurologic examination every other month. RESULTS: Between 1-6 cycles of systemic chemotherapy were administered (median, 4.5 cycles). and 6-19 cycles of regional chemotherapy were administered (median, 17 cycles). Toxicity included aseptic meningitis (three patients), radiation enteritis (one patient), and > or = Grade 3 (according to the National Cancer Institute Common toxicity Criteria) myelosuppression (four patients). Two patients required hospitalization for neutropenic fever and two patients required a transfusion (platelets in two patients and red blood cells in one patient). No treatment-related deaths were reported. A partial response was achieved in four patients, and two patients demonstrated progressive disease. The median duration of response was 9 months (range, 2-12 months). Overall survival ranged from 3-13 months (median, 10.5 months). The cause of death was progressive parenchymal brain disease in three patients, systemic disease in two patients, and leptomeningeal disease in one patient. CONCLUSIONS: In the small cohort of patients in the current study, combined modality therapy was found to have modest toxicity and palliative efficacy. (+info)Aesthesioneuroblastoma in a woodworker. (4/49)
A case is described of aesthesioneuroblastoma in a woodworker who had been exposed to wood dust for 25 years, without any individual or environmental protection. The case described supports the contention that occupational exposure to wood dust may have caused the neoplasm. (+info)Successful treatment of metastatic esthesioneuroblastoma. (5/49)
This case report describes a patient with a metastasised olfactorial esthesioneuroblastoma Hyams grade 4 who has been treated with debulking surgery and radiotherapy. After relapse in lymph node, lung and brain, he received additional irradiation and six cycles of carboplatin, vincristine and cyclophosphamide intravenously every three weeks. The patient has now been disease free for 7.8 years. Our data suggest that metastatic esthesioneuroblastoma is sensitive to platinum-based chemotherapy. This patient illustrates that this tumour is very sensitive to platinum-based chemotherapy and that durable complete response can be achieved, even in a metastatic ENB. (+info)Malignant tumors of the anterior skull base. (6/49)
BACKGROUND: Cancers of the paranasal sinuses or nasal cavity are the most common malignant tumors of the anterior skull base. Several types of tumors occur in this location, including cancers of endodermal, mesodermal, and epidermal origins. Although anterior skull base surgery is a relatively recent approach in treating these tumors, widespread changes have already occurred in procedural methods and treatment goals. METHODS: We review the tumor types that occur in the anterior skull base and discuss the current treatment options, including multimodal therapy and the team approach to surgery. Surgical techniques are also described. RESULTS: Management of anterior skull base cancer is complex due to the anatomic detail of the region and the variety of cancers that occur in this area. Currently, the "gold standard" for surgery is the anterior craniofacial approach. Combined with adjuvant radiation therapy, 5-year disease-free survival rates have increased to 50%, with some tumors such as adenocarcinomas and esthesioneuroblastomas reaching up to 80% 5-year survival rates. Potential complications include cerebrospinal fluid leakage, meningitis, abscess formation, and pneumocephalus. CONCLUSIONS: Treatment of anterior skull base cancer is complex due to the significant anatomic detail of the region and the variety of cancers that occur in this area. Multimodal therapy through a team approach is the optimal management approach for these tumors. (+info)Human achaete-scute homologue (hASH1) mRNA level as a diagnostic marker to distinguish esthesioneuroblastoma from poorly differentiated tumors arising in the sinonasal tract. (7/49)
Distinction of high-grade esthesioneuroblastomas from other poorly differentiated tumors arising in the nasal cavity is an important diagnostic challenge because it determines patient management and prognosis. The human achaete-scute homologue (hASH1) gene is critical in olfactory neuronal differentiation and is expressed in immature olfactory cells; therefore, it could have potential use as a diagnostic marker The aim of the present study was to determine the value of hASH1 messenger RNA (mRNA) levels in differentiating esthesioneuroblastoma from other poorly differentiated tumors. A real-time polymerase chain reaction assay was developed, permitting the comparative determination of hASH1 mRNA levels in triplicate in a double-blind pilot study including 24 frozen cases of esthesioneuroblastoma and poorly differentiated tumors. All 4 positive cases were esthesioneuroblastomas, and all 19 poorly differentiated tumors were negative. In addition, there was an inverse association between the grade of esthesioneuroblastomas and hASH1 mRNA levels. The hASH1 mRNA level might represent a useful tool for distinguishing esthesioneuroblastoma from poorly differentiated tumors of the sinonasal region. (+info)Combination chemotherapy (cyclophosphamide, doxorubicin, and vincristine with continuous-infusion cisplatin and etoposide) and radiotherapy with stem cell support can be beneficial for adolescents and adults with estheisoneuroblastoma. (8/49)
BACKGROUND: Adolescent-onset and adult-onset esthesioneuroblastoma is a rare disease and is considered incurable. In many patients, local resection and radiation are chosen as clinical therapy with or without chemotherapy. It was reported previously that local resection and radiotherapy led to temporary remission and, in many patients, recurrent disease. Although combination with chemotherapy has been regarded as promising, an effective regimen has not been established. In the current study, the authors investigated the effect and tolerability of the combination of chemotherapy, radiotherapy, and peripheral blood stem cell transplantation (PBSCT). METHODS: The study population included 12 patients with adolescent-onset and adult-onset esthesioneuroblastoma classified as Kadish Stage A-D. The patients received two cycles of combination chemotherapy, which consisted of cyclophosphamide, doxorubicin, and vincristine (CAD) with continuous-infusion cisplatin and etoposide (CVP). This was combined with radiotherapy with or without PBSCT. RESULTS: Nine of 12 patients (75%) obtained more than a partial response after only 2 cycles of chemotherapy. After radiation with or without PBSCT, six patients obtained a complete remission (CR). The longest survival was > 3 years. All patients who underwent PBSCT obtained a CR. The most severe side effects were loss of sodium and potassium induced by cisplatin-related renal tubular distress. Those abnormalities were temporary, and all patients recovered. CONCLUSIONS: The chemotherapy regimen with CADO and CVP does not require continuation for a long time and is very effective and tolerable for patients with adolescent-onset and adult-onset esthesioneuroblastoma. The combination with radiotherapy and PBSCT may lead to a CR without facial disfigurement. In this report, the authors discuss the feasibility and efficacy of this multidisciplinary approach. (+info)Esthesioneuroblastoma, also known as olfactory neuroblastoma, is a rare type of malignant tumor that develops in the upper part of the nasal cavity, near the area responsible for the sense of smell (olfaction). It arises from the olfactory nerve cells and typically affects adults between 20 to 50 years old, although it can occur at any age.
Esthesioneuroblastomas are characterized by their aggressive growth and potential to spread to other parts of the head and neck, as well as distant organs such as the lungs, bones, and bone marrow. Symptoms may include nasal congestion, nosebleeds, loss of smell, facial pain or numbness, bulging eyes, and visual disturbances.
Diagnosis is usually made through a combination of clinical examination, imaging studies (such as MRI or CT scans), and biopsy. Treatment typically involves surgical resection of the tumor, followed by radiation therapy and/or chemotherapy to reduce the risk of recurrence. Regular follow-up care is essential due to the possibility of late relapse.
Overall, prognosis varies depending on factors such as the stage of the disease at diagnosis, the patient's age, and the effectiveness of treatment. While some individuals may experience long-term survival or even cure, others may face more aggressive tumor behavior and a higher risk of recurrence.
Nose neoplasms refer to abnormal growths or tumors in the nasal cavity or paranasal sinuses. These growths can be benign (non-cancerous) or malignant (cancerous). Benign neoplasms are typically slow-growing and do not spread to other parts of the body, while malignant neoplasms can invade surrounding tissues and have the potential to metastasize.
Nose neoplasms can cause various symptoms such as nasal congestion, nosebleeds, difficulty breathing through the nose, loss of smell, facial pain or numbness, and visual changes if they affect the eye. The diagnosis of nose neoplasms usually involves a combination of physical examination, imaging studies (such as CT or MRI scans), and biopsy to determine the type and extent of the growth. Treatment options depend on the type, size, location, and stage of the neoplasm and may include surgery, radiation therapy, chemotherapy, or a combination of these approaches.
The nasal cavity is the air-filled space located behind the nose, which is divided into two halves by the nasal septum. It is lined with mucous membrane and is responsible for several functions including respiration, filtration, humidification, and olfaction (smell). The nasal cavity serves as an important part of the upper respiratory tract, extending from the nares (nostrils) to the choanae (posterior openings of the nasal cavity that lead into the pharynx). It contains specialized structures such as turbinate bones, which help to warm, humidify and filter incoming air.
Hyperostosis is a medical term that refers to an excessive growth or abnormal thickening of bone tissue. It can occur as a result of various conditions, such as inflammation, injury, or genetic disorders. The extra bone growth can cause pain, stiffness, and limited mobility in the affected area. In some cases, hyperostosis can also lead to deformities and other complications.
There are several types of hyperostosis, including:
1. Diffuse idiopathic skeletal hyperostosis (DISH): This is a condition that affects the spine, causing calcification and stiffening of the ligaments and bone spurs to form along the edges of the vertebrae. It is often asymptomatic but can cause pain and stiffness in some cases.
2. Flat bone hyperostosis: This type of hyperostosis affects the flat bones of the body, such as the skull, ribs, and pelvis. It can be caused by various conditions, including Paget's disease, fibrous dysplasia, and certain types of cancer.
3. Focal hyperostosis: This refers to localized areas of bone overgrowth that can occur in response to injury, infection, or inflammation. Examples include heterotopic ossification (the formation of bone in soft tissues) and Freiberg's infarction (a condition that affects the joint surface of the metatarsal bones in the foot).
4. Hyperostosis frontalis interna: This is a benign condition that causes thickening of the inner table of the frontal bone in the skull. It is more common in women and often asymptomatic but can cause headaches and other symptoms in some cases.
Treatment for hyperostosis depends on the underlying cause and severity of the condition. In some cases, no treatment may be necessary. However, if the condition causes pain or limits mobility, various treatments may be recommended, such as medication, physical therapy, or surgery.
Neuroectodermal tumors, primitive, peripheral (PNET) are a group of rare and aggressive malignancies that primarily affect children and young adults. These tumors arise from the primitive neuroectodermal cells, which are the precursors to the nervous system. PNETs can occur in various locations throughout the body, but when they occur outside the central nervous system (CNS), they are referred to as peripheral PNETs (pPNETs).
Peripheral PNETs are similar to Ewing sarcoma, another type of small, round blue cell tumor that arises from primitive neuroectodermal cells. In fact, some researchers consider pPNETs and Ewing sarcomas to be part of the same disease spectrum, known as the Ewing family of tumors (EFT).
Peripheral PNETs can occur in any part of the body, but they most commonly affect the bones and soft tissues of the trunk, extremities, and head and neck region. The symptoms of pPNET depend on the location and size of the tumor, but they may include pain, swelling, decreased mobility, and systemic symptoms such as fever and weight loss.
The diagnosis of pPNET typically involves a combination of imaging studies (such as MRI or CT scans), biopsy, and molecular testing. The treatment usually involves a multimodal approach that includes surgery, chemotherapy, and radiation therapy. Despite aggressive treatment, the prognosis for patients with pPNET remains poor, with a five-year survival rate of approximately 30%.
Paranasal sinus neoplasms refer to abnormal growths or tumors that develop within the paranasal sinuses, which are air-filled cavities located inside the skull near the nasal cavity. These tumors can be benign (noncancerous) or malignant (cancerous), and they can arise from various types of tissue within the sinuses, such as the lining of the sinuses (mucosa), bone, or other soft tissues.
Paranasal sinus neoplasms can cause a variety of symptoms, including nasal congestion, nosebleeds, facial pain or numbness, and visual disturbances. The diagnosis of these tumors typically involves a combination of imaging studies (such as CT or MRI scans) and biopsy to determine the type and extent of the tumor. Treatment options may include surgery, radiation therapy, chemotherapy, or a combination of these approaches, depending on the specific type and stage of the neoplasm.
The olfactory bulb is the primary center for the sense of smell in the brain. It's a structure located in the frontal part of the brain, specifically in the anterior cranial fossa, and is connected to the nasal cavity through tiny holes called the cribriform plates. The olfactory bulb receives signals from olfactory receptors in the nose that detect different smells, processes this information, and then sends it to other areas of the brain for further interpretation and perception of smell.
Olfactory receptor neurons (ORNs) are specialized sensory nerve cells located in the olfactory epithelium, a patch of tissue inside the nasal cavity. These neurons are responsible for detecting and transmitting information about odors to the brain. Each ORN expresses only one type of olfactory receptor protein, which is specific to certain types of odor molecules. When an odor molecule binds to its corresponding receptor, it triggers a signal transduction pathway that generates an electrical impulse in the neuron. This impulse is then transmitted to the brain via the olfactory nerve, where it is processed and interpreted as a specific smell. ORNs are continuously replaced throughout an individual's lifetime due to their exposure to environmental toxins and other damaging agents.
The olfactory nerve, also known as the first cranial nerve (I), is a specialized sensory nerve that is responsible for the sense of smell. It consists of thin, delicate fibers called olfactory neurons that are located in the upper part of the nasal cavity. These neurons have hair-like structures called cilia that detect and transmit information about odors to the brain.
The olfactory nerve has two main parts: the peripheral process and the central process. The peripheral process extends from the olfactory neuron to the nasal cavity, where it picks up odor molecules. These molecules bind to receptors on the cilia, which triggers an electrical signal that travels along the nerve fiber to the brain.
The central process of the olfactory nerve extends from the olfactory bulb, a structure at the base of the brain, to several areas in the brain involved in smell and memory, including the amygdala, hippocampus, and thalamus. Damage to the olfactory nerve can result in a loss of smell (anosmia) or distorted smells (parosmia).
Esthesioneuroblastoma
Anosmia
Neuroblastoma
List of MeSH codes (C04)
List of MeSH codes (C10)
International Classification of Diseases for Oncology
ASCL1
NIDCD's First Annual Olfactory Neuroblastoma (Esthesioneuroblastoma) Patient Education Meeting on February 29 | NIDCD
Radiosurgery for Intracranial Olfactory Neuroblastoma
Esthesioneuroblastoma - Wikipedia
Bone Cancer in the Skull: Types, Symptoms, and Survival
Esthesioneuroblastoma Clinical Presentation: History, Physical, Causes
Olfactory Neuroblastoma - Cancer Survivors Network
NIH Clinical Center Search the Studies: Study Number, Study Title
Types of Skull Base Tumors | University of Michigan Health
Esthesioneuroblastoma - Living with the Disease - Genetic and Rare Diseases Information Center
Biomarkers Search
What Is Nasal Cavity (Nose) Cancer? | What Is Sinus Cancer? | American Cancer Society
Transcription Factor Expression in Sinonasal Neuroendocrine Neoplasms and Olfactory Neuroblastoma (ONB): Hyams' Grades 1-3 ONBs...
Olfactory Neuroblastoma Treated by Minimally Invasive Endoscopic Resection and Postoperative Adjuvant Radiotherapy: A...
Release Date Request Code Change Type NCI Code CDISC Term Type CDISC Codelist (Short Name) CDISC Codelist (Long Name) Change...
DeCS - Changed terms
MeSH Browser
MeSH Browser
DeCS - Changed terms
DeCS - Changed terms
DeCS - Changed terms
Biotinylated Cynomolgus / Rhesus macaque PD-L1 / B7-H1 Protein, His,Avitagā¢ (MALS verified) - ACROBiosystems
Bio2Vec
HuGE Navigator|Genopedia|PHGKB
Adelaide Research & Scholarship: Search
Minimally Invasive Endoscopic Surgery for Malignant Tumors of the Skull Base | McGovern Medical School
Centers, HSCD - Scholarly Works - Arizona Board of Regents
Patient Stories | Johns Hopkins Neurology and Neurosurgery
Pesquisa | Portal Regional da BVS
Neuroblastoma14
- Esthesioneuroblastoma (ENB), also known as olfactory neuroblastoma, is a rare neoplasm originating from olfactory neuroepithelium. (medscape.com)
- 1. Kadish S, Goodman M, Wang CC. Olfactory neuroblastoma. (radiopaedia.org)
- Esthesioneuroblastoma also is called olfactory neuroblastoma. (middlesexhealth.org)
- Note: Esthesioneuroblastoma, also known as olfactory neuroblastoma, is believed to arise from the olfactory epithelium and its classification remains controversial. (medicalxpress.com)
- Mixed olfactory neuroblastoma and carcinoma. (uchicago.edu)
- An aggressive neoplasm derived from schneiderian epithelium and distinct from olfactory neuroblastoma. (uchicago.edu)
- The olfactory neuroblastoma (ONB) is a rare malignant tumor that arises in the nasal cavity and paranasal sinuses. (jcohns.org)
- ķź°ģ ź²½ģģøķ¬ģ¢ (olfactory neuroblastoma)ģ ėÆøė¶ķė ģ ź²½ ģøė°°ģ½ģģ źø°ģķė ģ ģ± ģ¢ ģģ¼ė” ė¹ė¶ė¹ė ģ¢ ģ ģ¤ 3%-5% ģ ė ė°ģķė ėė¬ø ģ§ķģ¼ė”, ģ¬ź³Øė ģ²ģ ģ“ė ė¹ģ¤ź²© ė±ģģ ģ£¼ė” ė°ģķģ¬ ė¶ė¹ė, ģģ ė° ėź° ė“ė” ģ¹Øė²ķė¤. (jcohns.org)
- The first symptom of an olfactory neuroblastoma is often chronic congestion on one side of the nose, which can continue for months or even years before a diagnosis is made. (upmc.com)
- If your doctor suspects that you may have an olfactory neuroblastoma, he or she will perform a variety of tests to diagnose the condition, including a physical exam and imaging tests such as MRI and CT scans . (upmc.com)
- Kiyota N, Tahara M, Fujii S. Non platinum-based chemotherapy with irinotecan plus docetaxel for advanced or metastatic olfactory neuroblastoma. (ijorl.com)
- In the front section of the skull base anterior cranial fossa, which contains the eye sockets and sinuses, the following tumors are more likely: Meningioma Olfactory neuroblastoma esthesioneuroblastoma Paranasal sinus cancer The central compartment of the skull base middle cranial fossa contains the sella turcica, a saddle-shaped bony structure in the skull base where the pituitary gland is located. (serenitylife.us)
- A malignant olfactory neuroblastoma arising from the olfactory epithelium of the superior nasal cavity and cribriform plate. (lookformedical.com)
- Esthesioneuroblastoma (ENB), also called olfactory neuroblastoma, is a rare malignant nasal cavity tumor originating from the olfactory neuroepithelium. (sehathub.com)
Nasal cavity6
- Esthesioneuroblastoma is a rare cancer of the nasal cavity. (wikipedia.org)
- Esthesioneuroblastoma occurs in the upper nasal cavity, near the optic nerves and optic chiasm. (wikipedia.org)
- Esthesioneuroblastoma (es-thee-zee-o-noo-row-blas-TOE-muh) is a rare type of cancer that starts in the upper part of the inside of the nose, known as the nasal cavity. (middlesexhealth.org)
- Esthesioneuroblastoma is a rare malignant neoplasm of oflactory neuroepithelium and usually located at the olfactory cleft at superior nasal cavity. (afpm.org.my)
- The mucous lining of the NASAL CAVITY , including lining of the nostril (vestibule) and the OLFACTORY MUCOSA . (lookformedical.com)
- Esthesioneuroblastoma is an uncommon malignant tumor originating in the upper nasal cavity. (neurosurgery-blog.com)
Epithelium3
- Esthesioneuroblastoma is of neurocrest origin, arising from olfactory sensory cells in the olfactory epithelium. (wikipedia.org)
- The olfactory epithelium consists of olfactory sensory cells, sustentacular cells and basal cells. (wikipedia.org)
- Esthesioneuroblastomas (ENBs) are undifferentiated tumors of neuroectodermal origin derived from the olfactory epithelium. (medscape.com)
Tumor9
- Due to the location of the tumor and its proximity to the cranial cavity, esthesioneuroblastoma can be highly invasive and challenging to treat. (wikipedia.org)
- Modified Kadish classification Dulguerov classification The preferred treatment for esthesioneuroblastoma is surgery followed by radiotherapy to prevent recurrence of the tumor. (wikipedia.org)
- In advanced stage esthesioneuroblastoma in pediatric patients, where surgery is no longer possible, aggressive chemotherapy and radiotherapy has resulted in some tumor control and long-term survival. (wikipedia.org)
- Esthesioneuroblastoma is a slow developing but malignant tumor with high recurrence rates because of its anatomical position. (wikipedia.org)
- Esthesioneuroblastoma usually begins as a growth of cells, called a tumor, inside the nose. (middlesexhealth.org)
- An olfactory groove meningioma is a rare benign tumor with a rather insidious course. (symptoma.com)
- Utility of Schwann/2E and Sox10 in distinguishing CD57-negative olfactory groove schwannoma from olfactory ensheathing cell tumor: A case report and review of the literature. (archivosdeneurociencias.org)
- Olfactory groove schwannoma is an uncommon intracranial tumor originating in the olfactory groove and is primarily associated with benign schwann cells. (neurosurgery.directory)
- Olfactory groove schwannoma is a rare type of tumor that arises in the olfactory groove of the skull. (neurosurgery.directory)
Anterior crani2
- Olfactory groove schwannomas are predominantly located in the anterior cranial fossa, often resulting in symptoms such as headaches, anosmia, visual disturbances, personality changes, and cognitive deficits. (neurosurgery.directory)
- Location: Olfactory groove schwannomas are found in the anterior cranial fossa, where the olfactory bulb and tract are located. (neurosurgery.directory)
Sinonasal2
- Hyam's histopathological grades for esthesioneuroblastoma Esthesioneuroblastoma can resemble small blue cell tumors like squamous cell carcinoma, sinonasal undifferentiated carcinoma, extranodal NK/T cell lymphoma, nasal type, rhabdomyosarcoma, Ewing/PNET, mucosal malignant melanoma and neuroendocrine carcinomas (NEC) that occur in the intranasal tract. (wikipedia.org)
- The Kadish classification is used for clinical classification of sinonasal tumors including esthesioneuroblastoma. (wikipedia.org)
Neuroblastomas5
- Olfactory neuroblastomas (or esthesioneuroblastomas ) are most frequently staged using a system proposed by Kadish et al. (radiopaedia.org)
- FDG PET and CT/MRI scanning were performed at the initial staging and/or the follow-up in 24 patients with rare HNCs, 10 with melanoma, 9 with sarcoma, 3 with olfactory neuroblastomas, and 2 with basal cell carcinoma. (e-ceo.org)
- We therefore evaluated the role of FDG PET for staging and monitoring patients with rare HNCs, including melanomas, basal cell carcinomas, sarcomas, and olfactory neuroblastomas (esthesioneuroblastomas). (e-ceo.org)
- If left untreated, olfactory neuroblastomas can be fatal. (upmc.com)
- Although most olfactory neuroblastomas grow slowly, some cases may progress rapidly and aggressively. (upmc.com)
Tumors including esthesioneu1
- Our series adds to the growing experience of expanded endonasal endoscopic surgery in the treatment of skull base tumors including esthesioneuroblastoma. (neurosurgery-blog.com)
Diagnosis4
- Preoperative differential diagnosis predilected an esthesioneuroblastoma. (archivosdeneurociencias.org)
- Differential diagnosis should consider other tumors, such as olfactory groove meningiomas and esthesioneuroblastomas. (neurosurgery.directory)
- Ectopic localization of esthesioneuroblastoma is even rarer and usually posed with a diagnostic dilemma and delay in the diagnosis and management, We report a rare case of ectopic esthesioneuroblastoma of the sphenoclivus with the presentation of intermittent unilateral epistaxis, intermittent intractable headache without anosmia. (afpm.org.my)
- Due to its rarity and unusual presentation, the diagnosis of ectopic esthesioneuroblastoma is difficult and can be misdiagnosed with the other type of malignancy. (afpm.org.my)
Symptoms2
- Also known as esthesioneuroblastoma , it's quite rare but can cause troubling and uncomfortable symptoms. (upmc.com)
- Symptoms: The symptoms of an olfactory groove schwannoma can vary depending on its size and location. (neurosurgery.directory)
Cell tumors1
- Why are olfactory ensheathing cell tumors so rare? (archivosdeneurociencias.org)
Surgical resection3
- Cyclophosphamide, vincristine and doxorubicin have been used as neoadjuvant chemotherapy drugs for grade C esthesioneuroblastoma before surgical resection, producing fair outcomes. (wikipedia.org)
- What is the typical outcome after complete surgical resection of an Olfactory Groove Schwannoma? (neurosurgery.directory)
- What is the primary goal of surgical resection in treating Olfactory Groove Schwannomas? (neurosurgery.directory)
Cribriform plate1
- Craniofacial resection can help preserve the optic nerves and brain while removing the cribriform plate, olfactory bulb, dura surrounding the bulb and even the orbital periosteum. (wikipedia.org)
Endoscopic2
- In this report, we performed a retrospective analysis of patients with esthesioneuroblastomas treated with a purely endonasal endoscopic approach and resection at the Johns Hopkins Hospital between January 2005 and April 2010. (neurosurgery-blog.com)
- In addition, we reviewed the literature and identified several overlapping case series of patients with esthesioneuroblastoma treated via a purely endoscopic technique. (neurosurgery-blog.com)
Metastasis1
- Retropharyngeal lymph node metastasis from esthesioneuroblastoma: a review of the therapeutic and prognostic implications. (radiopaedia.org)
Neuroectodermal1
- Arising from the upper nasal tract, esthesioneuroblastoma is believed to originate from sensory neuroepithelial cells, also known as neuroectodermal olfactory cells. (wikipedia.org)
Cranial1
- In which cranial fossa are Olfactory Groove Schwannomas predominantly located? (neurosurgery.directory)
Cancer3
- Testing can show if the cancer is esthesioneuroblastoma and it can give other information about the cancer that will help in making a treatment plan. (middlesexhealth.org)
- Esthesioneuroblastoma treatment usually involves surgery to remove the cancer. (middlesexhealth.org)
- Esthesioneuroblastoma (ENB) is a rare cancer of the olfactory mucosa, with no established molecular stratification to date. (hal.science)
Fossa1
- Sauvaget F, Francois P, Ben Ismail M, Thomas C, Velut S. Anterior fossa schwannoma mimicking an olfactory groove meningioma: case report and literature review. (archivosdeneurociencias.org)
Arises1
- When a schwannoma develops in the olfactory groove, it usually arises from the olfactory nerve or its branches. (neurosurgery.directory)
Groove12
- As an incidental finding of this MRI, a soft tissue mass in the olfactory groove was detected (2 cm x 8 mm). (symptoma.com)
- Computed tomography and magnetic resonance imaging showed a lesion in the frontal lobe that was deviated to the right and attached to the olfactory groove. (symptoma.com)
- The puzzling olfactory groove schwannoma: a systematic review. (archivosdeneurociencias.org)
- What is the primary location of Olfactory Groove Schwannomas? (neurosurgery.directory)
- Which of the following is NOT a common symptom of Olfactory Groove Schwannoma? (neurosurgery.directory)
- What is the primary treatment option for Olfactory Groove Schwannomas? (neurosurgery.directory)
- Which of the following statements is true regarding Olfactory Groove Schwannomas? (neurosurgery.directory)
- x] a) They often originate from Schwann cells in the olfactory groove. (neurosurgery.directory)
- Olfactory Groove Schwannomas can sometimes be confused with which other tumors? (neurosurgery.directory)
- According to the provided information, what is the controversial aspect of Olfactory Groove Schwannoma origin? (neurosurgery.directory)
- While olfactory groove schwannomas are generally benign, each case presents unique challenges, and a multidisciplinary approach is essential for comprehensive patient care. (neurosurgery.directory)
- This review also discusses case reports to shed light on the complex nature of olfactory groove schwannomas. (neurosurgery.directory)
Originate1
- a) They always originate from the olfactory nerve. (neurosurgery.directory)
Treatment4
- There is no consensus on an appropriate treatment approach of esthesioneuroblastoma because of the rarity of the disease. (wikipedia.org)
- Esthesioneuroblastoma: the impact of treatment modality. (radiopaedia.org)
- Esthesioneuroblastoma treatment usually includes surgery. (middlesexhealth.org)
- Treatment for esthesioneuroblastoma usually involves a team of experts with different specialties. (middlesexhealth.org)
Sinuses1
- Esthesioneuroblastoma can grow and get into the sinuses, eyes and brain. (middlesexhealth.org)
Complications2
- Les complications orbitaires et endocrĆ¢niennes des sinusites aiguĆ«s infectieuses posent un problĆØme diagnostique et thĆ©rapeutique Le but de notre travail est de proposer un algorithme de prise en charge de ces complications Ć travers une revue de littĆ©rature Les sinusites de la base du crĆ¢ne (frontal, sphĆ©noĆÆdal et Ć©thmoĆÆdal) sont les plus frĆ©quents en cause de complications endocrĆ¢niennes. (ajol.info)
- Les complications orbitaires sont traitƩes par des antibiotiques visant les bactƩries en cause avec des indications chirurgicales selon la classification scannographique de Chandler. (ajol.info)
Pediatric1
- If the person with esthesioneuroblastoma is a child, the team also might include specialists in pediatric surgery and oncology. (middlesexhealth.org)
Genetic1
- There is limited research on the genetic role in esthesioneuroblastoma development. (wikipedia.org)
Nerve1
- Olfactory nerve is not directly associated with these lesions. (archivosdeneurociencias.org)
Consists1
- Esthesioneuroblastoma consists of lobular sheets with neurofibrullar fibers and rosettes. (wikipedia.org)
Cases1
- Interestingly, 80% of the esthesioneuroblastoma (ENB) cases published in the literature since Berger and Luc described the first case in 1924 have been identified in the last few decades. (medscape.com)
Patients1
- A total of eight patients with esthesioneuroblastoma, five men and three women, were identified. (neurosurgery-blog.com)
Case Report1
- Besharatirad M, Sharifi G, Bidari Zerehpoosh F. An olfactory Schwannoma mimicking esthesioneuroblastoma: A case report. (archivosdeneurociencias.org)